LENZ Therapeutics to Join Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2024 -- LENZ Therapeutics, Inc. (Nasdaq: LENZ), a biopharmaceutical company in the advanced stages of clinical development, is pioneering an aceclidine-based eye drop aimed at improving near vision for individuals with presbyopia. The company has recently announced its participation in several key investor conferences.

At the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, the company management will engage in one-on-one meetings on Wednesday, September 4, 2024. Following this, LENZ Therapeutics will attend the Wells Fargo Securities 2024 Healthcare Conference in Boston, MA, with one-on-one meetings scheduled for Thursday, September 5, 2024.

Further, LENZ Therapeutics will be represented at the H.C. Wainwright 26th Annual Global Investment Conference, also in New York, NY. Here, management will deliver a corporate presentation on Tuesday, September 10, 2024, at 12:30 PM ET, in addition to holding individual meetings.

On Wednesday, September 18, 2024, the company is slated to present at the Cantor Global Healthcare Conference in New York, NY, at 10:55 AM ET, along with more one-on-one meetings. The corporate presentation at this event will be accessible via a live audio webcast on the LENZ Therapeutics website in the Investors & Media section for 90 days post-presentation. A recording of the webcast will remain available for 30 days after the event.

LENZ Therapeutics is dedicated to developing and bringing to market an innovative aceclidine-based eye drop to improve vision for individuals with presbyopia, a common age-related condition affecting approximately 1.8 billion people worldwide, including 128 million in the United States. Their lead product candidate, LNZ100, is a preservative-free, single-use eye drop intended for daily use. This candidate underwent assessment in the pivotal Phase 3 CLARITY study for its effectiveness as a treatment for presbyopia.

The company has already submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval to market LNZ100. LENZ Therapeutics is passionate about providing an optimal pharmaceutical solution for presbyopia, pledging to enhance vision for all users throughout the day. The company operates out of San Diego, California. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!